We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
–
Cap. Flow
+$524M
Cap. Flow %
386.8%
Top 10 Hldgs %
40.45%
Holding
204
New
204
Increased
–
Reduced
–
Closed
–

Top Buys

1
GILD icon
Gilead Sciences
GILD
+$13M
2
CMG icon
Chipotle Mexican Grill
CMG
+$8.2M
3
CELG
Celgene Corp
CELG
+$6.34M
4
CMRX
Chimerix, Inc.
CMRX
+$5.55M
5
DYAX
DYAX CORPORATION
DYAX
+$5.42M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 43.09%
2 Consumer Discretionary 6.1%
3 Materials 3.81%
4 Consumer Staples 3.68%
5 Technology 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMCR
51
DELISTED
KEURIG GREEN MTN INC
GMCR
$694K 0.51%
+7,710
New +$479K
CASC
52
DELISTED
Cascadian Therapeutics, Inc.
CASC
$666K 0.49%
+50,002
New +$861K
RLYP
53
CALL
DELISTED
RELYPSA INC COM
RLYP
$665K 0.49%
+111,600
New +$2.4M
BLUE
54
DELISTED
bluebird bio
BLUE
$644K 0.48%
+774
New +$773K
BHI
55
DELISTED
Baker Hughes
BHI
$603K 0.44%
+13,066
New +$669K
TAP icon
56
CALL
Molson Coors Class B
TAP
$7.84B
$598K 0.44%
+78,200
New +$7.05M
AEGR
57
DELISTED
Aegerion Pharmaceuticals
AEGR
$590K 0.44%
+58,445
New +$703K
PFE icon
58
Pfizer
PFE
$143B
$583K 0.43%
+19,046
New +$599K
CELG
59
PUT
DELISTED
Celgene Corp
CELG
$567K 0.42%
+55,700
New +$6.44M
OPK icon
60
PUT
Opko Health
OPK
$899M
$548K 0.4%
+50,000
New +$501K
TIF
61
DELISTED
Tiffany & Co.
TIF
$544K 0.4%
+7,129
New +$557K
LRMR icon
62
Larimar Therapeutics
LRMR
$381M
$502K 0.37%
+6,648
New +$1.07M
GMCR
63
CALL
DELISTED
KEURIG GREEN MTN INC
GMCR
$476K 0.35%
+13,900
New +$864K
AKBA icon
64
Akebia Therapeutics
AKBA
$376M
$467K 0.34%
+36,156
New +$369K
BUD icon
65
AB InBev
BUD
$157B
$463K 0.34%
+3,700
New +$448K
QCOM icon
66
Qualcomm
QCOM
$180B
$460K 0.34%
+9,200
New +$491K
PGEN icon
67
PUT
Precigen
PGEN
$1.76B
$440K 0.32%
+44,901
New +$1.51M
FPRX
68
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$436K 0.32%
+10,505
New +$352K
SNDK
69
CALL
DELISTED
SANDISK CORP
SNDK
$432K 0.32%
+63,000
New +$4.61M
KMI icon
70
PUT
Kinder Morgan
KMI
$72.4B
$414K 0.31%
+19,595
New +$467K
BCRX icon
71
BioCryst Pharmaceuticals
BCRX
$2.31B
$409K 0.3%
+39,600
New +$394K
ALKS icon
72
PUT
Alkermes
ALKS
$8.66B
$372K 0.27%
+52,400
New +$3.67M
CLVS
73
DELISTED
Clovis Oncology, Inc.
CLVS
$338K 0.25%
+9,660
New +$623K
ALXN
74
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$325K 0.24%
+10,000
New +$1.75M
MXIM
75
DELISTED
Maxim Integrated Products
MXIM
$323K 0.24%
+8,500
New +$325K
1 2
3
4 5

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for FT Options, which disclosed 204 positions worth $136M. Its ten largest holdings account for 40% of the portfolio.

Its largest position is Gilead Sciences: 125,233 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, followed by Consumer Discretionary and Materials.

  • FT Options's largest Q4 2015 buy was Gilead Sciences: 125,233 shares worth $12.7M.
  • FT Options's ten largest holdings make up 40% of its $136M portfolio in Q4 2015.
  • FT Options disclosed 204 positions in Q4 2015, its first 13F filing on record.

Based on FT Options's 13F filing for Q4 2015, filed 5 Feb 2016.